DATE: Tuesday, September 11, 2018

TIME: 10:00AM EDT, 16:00 CET

With increasing safety requirements, and time and financial pressure, the development of new drugs, and the execution of basic research projects, are presenting multiple challenges. To be successful in such a competitive environment, it is more important than ever to select the right approach to execute the different aspects of the multiple tasks needed to develop a new drug or to execute fundamental research. In this Webinar, examples will be presented where different technologies have been compared to analyze the potency of transcription inhibitors, and to measure the cytotoxic potential of test compounds in relevant cellular models, using various assay and reader platforms. The relative advantages of each method will be discussed, and the key points important for the project efficiency and cost will be highlighted. Dr. Vincent Dupriez (PerkinElmer) will first make a general introduction, and will then present data generated by collaborators, about “Improving dual reporter gene assays quality and efficiency: use of twinlite for studying transcriptional regulation by viral inhibitor proteins.”  And “Selecting the best option for PBMC luminescent cell viability assays.” Dr. Maria Kuzikov (Fraunhofer IME ScreeningPort) will present the data generated at the Fraunhofer IME ScreeningPort about “An efficient method, space and cost-saving, to assess cell viability using the ATPlite reagent and the VICTOR Nivo™ Multimode Plate Reader and will discuss the advantages of using this platform. Dr. Jeanine Hinterneder (PerkinElmer) will speak about “Improving the predictability of cytotoxicity tests by moving to 3D cell culture models.” And will illustrate the different 3D cell culture options to grow spheroids and the methods developed to analyze the viability of such spheroids.

Learning Objectives:

• Learn about differences in reporter gene assays options, and their impact on the cost, quality and ease of execution of R&D work
• Learn about different options for cell viability testing, the impact of such differences on the execution of R&D work, and about the possibility to run such assays on relevant cellular models.